retatrutide efficacy clinical trials The Effect of on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity Weight Loss Drug Pipeline 2025

By contrast, both OMMs reported a significantly lower risk for all-cause mortality compared to placebo (Table 4)

Key Takeaways STDEI GLP-1 mimics incretin hormones, enhancing insulin secretion and sensitivity while promoting satiety and reducing appetite

Richard, University of Gothenburg, Sweden Updates Copyright 2025 Aristizbal-Colorado, Corredor-Rengifo, Sierra-Castillo, Lpez-Corredor, Vernaza-Trujillo, Weir-Restrepo, Izquierdo-Condoy, Ortiz-Prado, Rico-Fontalvo, Gmez-Mesa, Abreu-Lomba and Rivera-Martnez

Self-administration of injectable medications carries risks including infection, incorrect dosing, and adverse reactions

Figure 1: Landscape of GLP-1 coverage in Medicaid for weight loss indication "Recent change" is relative to KFFs August 2024 report